ERBB2 and breast cancer: Human epidermal growth factor receptor 2-positive (HER2+) disease, which represents nearly 15% of all breast cancer diagnoses, also remains a therapeutic challenge due to multiple potential mechanisms of therapeutic resistance, despite the availability of anti-HER2 therapies (3–5).